<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03279224</url>
  </required_header>
  <id_info>
    <org_study_id>STAN-FMT-WCH-2016</org_study_id>
    <nct_id>NCT03279224</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder</brief_title>
  <official_title>A Randomized Controlled Trial of the Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valerie Taylor</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Women's College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Every human harbors complex microbial communities (collectively, the human 'microbiome') that
      cover the skin and the body's mucosal surfaces. There is mounting evidence of an interaction
      between the intestinal microbiota, the gut, and the central nervous system (CNS) in what is
      recognized as the microbiome-gut-brain axis. Based on this compelling body of evidence, there
      is growing enthusiasm for work that is focused on translating this emerging association into
      novel therapies for psychiatric illness.

      Fecal microbiota transplantation(FMT) is a technique in which gut bacteria are transferred
      from a healthy screened donor to a patient, with the goal to introduce or restore a stable
      microbial community in the gut.There are no clinical trials examining the impact of FMT on
      Bipolar Disorder (BD). However, there is biological rationale to support this type of
      treatment, given the known inflammatory underpinnings of this illness.

      The objective of this study is to assess the effectiveness of this very novel therapy
      targeting the gut-brain axis, FMT, to treat bipolar depression.

      Study Hypotheses:

      Main hypothesis: FMT from healthy donors to patients with BD depression will improve
      depression symptoms as an adjunct to approved medication.

      Secondary hypotheses:

        1. FMT will also reduce anxiety and global function

        2. FMT is safe and will be well tolerated by the patients

        3. Improvements in clinical parameters will be associated with specific changes in the
           intestinal microbiome and/or metabolites in stool and serum
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goals of this proof of concept study are to determine the effectiveness, safety
      and tolerability of FMT in adults with BD depression.

      Objective 1: To evaluate the effectiveness of the combination of a currently accepted
      approved therapy for BD depression + FMT in individuals with BD depression. This will be
      assessed through a change in the Montgomery-Ãsberg Depression Rating Scale (MADRS) total
      score from baseline (pre-intervention) to the final visit (week 24). The investigators will
      also assess the proportion of patients withdrawing from study due to inadequate control of
      depressive symptoms.

      Secondary objective 2: To evaluate the effectiveness of FMT on anxiety symptoms and global
      function/overall improvement in participants with BD depression. Secondary objective 3: To
      determine the safety and tolerability of FMT in individuals with BD depression. Safety will
      be evaluated by solicited and unsolicited adverse events, including serious adverse events,
      throughout the study period. Tolerability will be assessed using the Toronto Side Effect
      Scale (TSES). This is a 32-item instrument that is designed to establish incidence,
      frequency, and severity of CNS, gastrointestinal, and sexual side effects.

      Secondary objective 4: To assess the effect of FMT on microbiome profile (community structure
      and functional metagenome) and fecal metabolome. Changes in fecal microbiome profile and
      fecal metabolome from baseline to the final visit will be assessed using next generation
      sequencing and nuclear magnetic resonance (NMR) spectrometry, respectively. Changes in mood
      rating scales will be correlated with a specific microbiome and metabolome signature.
      Intestinal microbiome and metabolome of healthy donors will also be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">September 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Adults with BD depression being treated with an approved medication will be assigned to either allogenic FMT (from a healthy, screened individual with no personal or family history of an Axis 1 disorder) or autologous FMT (re-infusion of own feces)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Both the patient and the study team (clinical team, study coordinator, data analyst) will be blinded to group assignments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the MADRS total score from baseline (pre-intervention) to the final visit (week 24).</measure>
    <time_frame>Every 2 weeks for 24 weeks</time_frame>
    <description>The MADRS score will be used to assess the effectiveness of the combination of a currently accepted approved therapy plus FMT on depression symptoms. The MADRS score will also help assess the percentage of patients who show inadequate control of depressive symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the the Clinical Global Impression (CGI) scale</measure>
    <time_frame>Every 2 weeks for 24 weeks</time_frame>
    <description>The effectiveness of Approved treatment + FMT in controlling anxiety symptoms and global function/Overall improvement will be assessed through the CGI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the the World Health Organization Quality of life (WHOQOL-BREF) rating</measure>
    <time_frame>Every 2 weeks for 24 weeks</time_frame>
    <description>The effectiveness of Approved treatment + FMT in improving the quality of life of bipolar depression patients will be assessed through the World Health Organization Quality of life (WHOQOL-BREF) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects as reported on the Toronto Side Effect Scale (TSES)</measure>
    <time_frame>Every 2 weeks for 24 weeks</time_frame>
    <description>The tolerability of FMT will be assessed using the Toronto Side effects Scale (TSES)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fecal microbiome profile</measure>
    <time_frame>stool sample collected at Baseline (Visit 2), week 12 and at week 24</time_frame>
    <description>Stool samples will be collected and analysed using next generation sequencing to examine changes in Changes in fecal microbiome profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fecal Matabolome</measure>
    <time_frame>stool sample collected at Baseline (Visit 2), week 12 and at week 24</time_frame>
    <description>Stool samples will be collected and analysed using nuclear magnetic resonance (NMR) spectrometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Allogenic FMT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) from a healthy, screened individual with no personal or family history of an Axis 1 disorder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous FMT</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) by re-infusion of their own feces donated earlier in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogenic FMT</intervention_name>
    <description>Fifty (50) g of screened donor feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.
2.The volume of fecal filtrate corresponding to fifty (50) g of donor stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.
3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy.</description>
    <arm_group_label>Allogenic FMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous FMT</intervention_name>
    <description>1. Fifty (50) g of the participant's feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.
3.The volume of fecal filtrate corresponding to fifty (50) g of participant's stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.
3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy.</description>
    <arm_group_label>Autologous FMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 18-65 years of age

          2. Outpatient status

          3. Have a diagnosis of bipolar disorder (BD) (type I or II) according to the Mini
             International Neuropsychiatric Interview (MINI)

          4. Have been on a stable first line treatment for BD depression at an adequate dose for
             at least 8 weeks prior to study entry

          5. Suffer from a current depressive episode (Montgomery-Åsberg Depression Rating Scale
             (MADRS) score at screening and baseline of ≥ 20)

        Exclusion Criteria:

          1. DSM-IV criteria for substance abuse within the last 6 months or lifetime dependency

          2. Active eating disorders

          3. Schizophrenia or schizoaffective disorder

          4. Current psychotic symptoms

          5. A Young Mania Rating Scale (YMRS) score of ≥12 at screening

          6. Active suicidality

          7. Regular intake of non-steroidal anti-inflammatory drugs or iron supplements in the 3
             months prior to study entry

          8. Use of prebiotics or probiotics for medical purposes, use of antibiotics or any
             experimental drug in the 3 months prior to study entry

          9. Chronic gastrointestinal diseases

         10. Conditions causing immunosuppression

         11. A significant bleeding disorder

         12. Any contraindication to colonoscopy

         13. Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerie Taylor, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asem Bala, MSc, CCRP</last_name>
    <phone>416-323-6400</phone>
    <phone_ext>2301</phone_ext>
    <email>asem.bala@wchospital.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Women's college Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Sidhu</last_name>
      <phone>416-351-3732</phone>
      <phone_ext>2723</phone_ext>
      <email>Melissa.sidhu@wchospital.ca</email>
    </contact>
    <investigator>
      <last_name>Valerie Taylor, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://mtop.ca/funded-projects/</url>
    <description>Microbiota Therapeutics Outcomes Program (MTOP)</description>
  </link>
  <reference>
    <citation>Brietzke E, Stertz L, Fernandes BS, Kauer-Sant'anna M, Mascarenhas M, Escosteguy Vargas A, Chies JA, Kapczinski F. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009 Aug;116(3):214-7. doi: 10.1016/j.jad.2008.12.001. Epub 2009 Feb 28.</citation>
    <PMID>19251324</PMID>
  </reference>
  <reference>
    <citation>Guloksuz S, Cetin EA, Cetin T, Deniz G, Oral ET, Nutt DJ. Cytokine levels in euthymic bipolar patients. J Affect Disord. 2010 Nov;126(3):458-62. doi: 10.1016/j.jad.2010.04.027.</citation>
    <PMID>20537397</PMID>
  </reference>
  <reference>
    <citation>Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, Wang W, Tang W, Tan Z, Shi J, Li L, Ruan B. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun. 2015 Aug;48:186-94. doi: 10.1016/j.bbi.2015.03.016. Epub 2015 Apr 13.</citation>
    <PMID>25882912</PMID>
  </reference>
  <reference>
    <citation>Naseribafrouei A, Hestad K, Avershina E, Sekelja M, Linløkken A, Wilson R, Rudi K. Correlation between the human fecal microbiota and depression. Neurogastroenterol Motil. 2014 Aug;26(8):1155-62. doi: 10.1111/nmo.12378. Epub 2014 Jun 1.</citation>
    <PMID>24888394</PMID>
  </reference>
  <reference>
    <citation>Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil. 2011 Mar;23(3):255-64, e119. doi: 10.1111/j.1365-2982.2010.01620.x. Epub 2010 Nov 5.</citation>
    <PMID>21054680</PMID>
  </reference>
  <reference>
    <citation>Diaz Heijtz R, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):3047-52. doi: 10.1073/pnas.1010529108. Epub 2011 Jan 31.</citation>
    <PMID>21282636</PMID>
  </reference>
  <reference>
    <citation>Frémont M, Coomans D, Massart S, De Meirleir K. High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients. Anaerobe. 2013 Aug;22:50-6. doi: 10.1016/j.anaerobe.2013.06.002. Epub 2013 Jun 19.</citation>
    <PMID>23791918</PMID>
  </reference>
  <reference>
    <citation>Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol. 2013 Jan;29(1):79-84. doi: 10.1097/MOG.0b013e32835a4b3e. Review.</citation>
    <PMID>23041678</PMID>
  </reference>
  <reference>
    <citation>Xu MQ, Cao HL, Wang WQ, Wang S, Cao XC, Yan F, Wang BM. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol. 2015 Jan 7;21(1):102-11. doi: 10.3748/wjg.v21.i1.102. Review.</citation>
    <PMID>25574083</PMID>
  </reference>
  <reference>
    <citation>Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012 Oct;143(4):913-6.e7. doi: 10.1053/j.gastro.2012.06.031. Epub 2012 Jun 20. Erratum in: Gastroenterology. 2013 Jan;144(1):250.</citation>
    <PMID>22728514</PMID>
  </reference>
  <reference>
    <citation>Zoller V, Laguna AL, Prazeres Da Costa O, Buch T, Göke B, Storr M. [Fecal microbiota transfer (FMT) in a patient with refractory irritable bowel syndrome]. Dtsch Med Wochenschr. 2015 Aug;140(16):1232-6. doi: 10.1055/s-0041-103798. Epub 2015 Aug 11. German.</citation>
    <PMID>26261935</PMID>
  </reference>
  <reference>
    <citation>Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2014 Dec;8(12):1569-81. doi: 10.1016/j.crohns.2014.08.006. Epub 2014 Sep 13. Review.</citation>
    <PMID>25223604</PMID>
  </reference>
  <reference>
    <citation>Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, Moore T, Wu G. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology. 2015 Jul;149(1):223-37. doi: 10.1053/j.gastro.2015.05.008. Epub 2015 May 15. Review.</citation>
    <PMID>25982290</PMID>
  </reference>
  <reference>
    <citation>EISEMAN B, SILEN W, BASCOM GS, KAUVAR AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958 Nov;44(5):854-9.</citation>
    <PMID>13592638</PMID>
  </reference>
  <reference>
    <citation>Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, Bisson JF, Rougeot C, Pichelin M, Cazaubiel M, Cazaubiel JM. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2011 Mar;105(5):755-64. doi: 10.1017/S0007114510004319. Epub 2010 Oct 26.</citation>
    <PMID>20974015</PMID>
  </reference>
  <reference>
    <citation>Dickerson FB, Stallings C, Origoni A, Katsafanas E, Savage CL, Schweinfurth LA, Goga J, Khushalani S, Yolken RH. Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial. Prim Care Companion CNS Disord. 2014;16(1). pii: PCC.13m01579. doi: 10.4088/PCC.13m01579. Epub 2014 Feb 13.</citation>
    <PMID>24940526</PMID>
  </reference>
  <reference>
    <citation>Rao AV, Bested AC, Beaulne TM, Katzman MA, Iorio C, Berardi JM, Logan AC. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog. 2009 Mar 19;1(1):6. doi: 10.1186/1757-4749-1-6.</citation>
    <PMID>19338686</PMID>
  </reference>
  <reference>
    <citation>Logan AC, Katzman M. Major depressive disorder: probiotics may be an adjuvant therapy. Med Hypotheses. 2005;64(3):533-8.</citation>
    <PMID>15617861</PMID>
  </reference>
  <reference>
    <citation>Girard SA, Bah TM, Kaloustian S, Lada-Moldovan L, Rondeau I, Tompkins TA, Godbout R, Rousseau G. Lactobacillus helveticus and Bifidobacterium longum taken in combination reduce the apoptosis propensity in the limbic system after myocardial infarction in a rat model. Br J Nutr. 2009 Nov;102(10):1420-5. doi: 10.1017/S0007114509990766. Epub 2009 Jun 29.</citation>
    <PMID>19563693</PMID>
  </reference>
  <reference>
    <citation>Sullivan A, Nord CE. Probiotics and gastrointestinal diseases. J Intern Med. 2005 Jan;257(1):78-92. Review.</citation>
    <PMID>15606379</PMID>
  </reference>
  <reference>
    <citation>Gareau MG, Jury J, MacQueen G, Sherman PM, Perdue MH. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut. 2007 Nov;56(11):1522-8. Epub 2007 Mar 5. Erratum in: Gut. 2008 Apr;57(4):560.</citation>
    <PMID>17339238</PMID>
  </reference>
  <reference>
    <citation>Eutamene H, Bueno L. Role of probiotics in correcting abnormalities of colonic flora induced by stress. Gut. 2007 Nov;56(11):1495-7.</citation>
    <PMID>17938427</PMID>
  </reference>
  <reference>
    <citation>Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG. The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat. J Psychiatr Res. 2008 Dec;43(2):164-74. doi: 10.1016/j.jpsychires.2008.03.009. Epub 2008 May 5.</citation>
    <PMID>18456279</PMID>
  </reference>
  <reference>
    <citation>Camilleri M. Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol. 2006 Mar;40(3):264-9. Review.</citation>
    <PMID>16633134</PMID>
  </reference>
  <reference>
    <citation>Luna RA, Foster JA. Gut brain axis: diet microbiota interactions and implications for modulation of anxiety and depression. Curr Opin Biotechnol. 2015 Apr;32:35-41. doi: 10.1016/j.copbio.2014.10.007. Epub 2014 Nov 21. Review.</citation>
    <PMID>25448230</PMID>
  </reference>
  <reference>
    <citation>Maes M, Kubera M, Leunis JC, Berk M. Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J Affect Disord. 2012 Dec 1;141(1):55-62. doi: 10.1016/j.jad.2012.02.023. Epub 2012 Mar 11.</citation>
    <PMID>22410503</PMID>
  </reference>
  <reference>
    <citation>Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett. 2008 Feb;29(1):117-24.</citation>
    <PMID>18283240</PMID>
  </reference>
  <reference>
    <citation>Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, Tóth M, Korecka A, Bakocevic N, Ng LG, Kundu P, Gulyás B, Halldin C, Hultenby K, Nilsson H, Hebert H, Volpe BT, Diamond B, Pettersson S. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. 2014 Nov 19;6(263):263ra158. doi: 10.1126/scitranslmed.3009759. Erratum in: Sci Transl Med. 2014 Dec 10;6(266):266er7. Guan, Ng Lai [corrected to Ng, Lai Guan].</citation>
    <PMID>25411471</PMID>
  </reference>
  <reference>
    <citation>Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012 Nov;10(11):735-42. doi: 10.1038/nrmicro2876. Epub 2012 Sep 24. Review.</citation>
    <PMID>23000955</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Kasper LH. The role of microbiome in central nervous system disorders. Brain Behav Immun. 2014 May;38:1-12. doi: 10.1016/j.bbi.2013.12.015. Epub 2013 Dec 25. Review.</citation>
    <PMID>24370461</PMID>
  </reference>
  <reference>
    <citation>Petra AI, Panagiotidou S, Hatziagelaki E, Stewart JM, Conti P, Theoharides TC. Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation. Clin Ther. 2015 May 1;37(5):984-95. doi: 10.1016/j.clinthera.2015.04.002. Review.</citation>
    <PMID>26046241</PMID>
  </reference>
  <reference>
    <citation>Bangsgaard Bendtsen KM, Krych L, Sørensen DB, Pang W, Nielsen DS, Josefsen K, Hansen LH, Sørensen SJ, Hansen AK. Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse. PLoS One. 2012;7(10):e46231. doi: 10.1371/journal.pone.0046231. Epub 2012 Oct 2.</citation>
    <PMID>23056268</PMID>
  </reference>
  <reference>
    <citation>Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002 Jun;59(6):530-7.</citation>
    <PMID>12044195</PMID>
  </reference>
  <reference>
    <citation>Cryan JF, O'Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil. 2011 Mar;23(3):187-92. doi: 10.1111/j.1365-2982.2010.01664.x.</citation>
    <PMID>21303428</PMID>
  </reference>
  <reference>
    <citation>Forsythe P, Sudo N, Dinan T, Taylor VH, Bienenstock J. Mood and gut feelings. Brain Behav Immun. 2010 Jan;24(1):9-16. doi: 10.1016/j.bbi.2009.05.058. Epub 2009 May 28. Review.</citation>
    <PMID>19481599</PMID>
  </reference>
  <reference>
    <citation>Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009 May;6(5):306-14. doi: 10.1038/nrgastro.2009.35. Review.</citation>
    <PMID>19404271</PMID>
  </reference>
  <reference>
    <citation>Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, Kubo C, Koga Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol. 2004 Jul 1;558(Pt 1):263-75. Epub 2004 May 7.</citation>
    <PMID>15133062</PMID>
  </reference>
  <reference>
    <citation>Goehler LE, Gaykema RP, Opitz N, Reddaway R, Badr N, Lyte M. Activation in vagal afferents and central autonomic pathways: early responses to intestinal infection with Campylobacter jejuni. Brain Behav Immun. 2005 Jul;19(4):334-44.</citation>
    <PMID>15944073</PMID>
  </reference>
  <reference>
    <citation>Lyte M, Li W, Opitz N, Gaykema RP, Goehler LE. Induction of anxiety-like behavior in mice during the initial stages of infection with the agent of murine colonic hyperplasia Citrobacter rodentium. Physiol Behav. 2006 Oct 30;89(3):350-7. Epub 2006 Aug 2.</citation>
    <PMID>16887154</PMID>
  </reference>
  <reference>
    <citation>Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16050-5. doi: 10.1073/pnas.1102999108. Epub 2011 Aug 29.</citation>
    <PMID>21876150</PMID>
  </reference>
  <reference>
    <citation>Kunz M, Ceresér KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, Belmonte-de-Abreu PS, Kauer-Sant'Anna M, Kapczinski F, Gama CS. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev Bras Psiquiatr. 2011 Sep;33(3):268-74.</citation>
    <PMID>21971780</PMID>
  </reference>
  <reference>
    <citation>Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, Yatham LN. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol. 2009 May;12(4):447-58. doi: 10.1017/S1461145708009310. Epub 2008 Sep 4.</citation>
    <PMID>18771602</PMID>
  </reference>
  <reference>
    <citation>Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience. 2010 Nov 10;170(4):1179-88. doi: 10.1016/j.neuroscience.2010.08.005. Epub 2010 Aug 6.</citation>
    <PMID>20696216</PMID>
  </reference>
  <reference>
    <citation>Padmos RC, Van Baal GC, Vonk R, Wijkhuijs AJ, Kahn RS, Nolen WA, Drexhage HA. Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: a twin study. Arch Gen Psychiatry. 2009 Sep;66(9):957-65. doi: 10.1001/archgenpsychiatry.2009.116.</citation>
    <PMID>19736352</PMID>
  </reference>
  <reference>
    <citation>Baldessarini RJ, Tondo L. Suicide risk and treatments for patients with bipolar disorder. JAMA. 2003 Sep 17;290(11):1517-9. Erratum in: JAMA. 2004 Jan 14;291(2):186.</citation>
    <PMID>13129995</PMID>
  </reference>
  <reference>
    <citation>Colom F, Vieta E, Martínez-Arán A, Reinares M, Benabarre A, Gastó C. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry. 2000 Aug;61(8):549-55.</citation>
    <PMID>10982196</PMID>
  </reference>
  <reference>
    <citation>Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov;163(11):1905-17.</citation>
    <PMID>17074942</PMID>
  </reference>
  <reference>
    <citation>Tang MS, Poles J, Leung JM, Wolff MJ, Davenport M, Lee SC, Lim YA, Chua KH, Loke P, Cho I. Inferred metagenomic comparison of mucosal and fecal microbiota from individuals undergoing routine screening colonoscopy reveals similar differences observed during active inflammation. Gut Microbes. 2015;6(1):48-56. doi: 10.1080/19490976.2014.1000080. Epub 2015 Jan 20.</citation>
    <PMID>25559083</PMID>
  </reference>
  <reference>
    <citation>Parthasarathy G, Chen J, Chen X, Chia N, O'Connor HM, Wolf PG, Gaskins HR, Bharucha AE. Relationship Between Microbiota of the Colonic Mucosa vs Feces and Symptoms, Colonic Transit, and Methane Production in Female Patients With Chronic Constipation. Gastroenterology. 2016 Feb;150(2):367-79.e1. doi: 10.1053/j.gastro.2015.10.005. Epub 2015 Oct 13.</citation>
    <PMID>26460205</PMID>
  </reference>
  <reference>
    <citation>Bajaj JS, Betrapally NS, Hylemon PB, Heuman DM, Daita K, White MB, Unser A, Thacker LR, Sanyal AJ, Kang DJ, Sikaroodi M, Gillevet PM. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology. 2015 Oct;62(4):1260-71. doi: 10.1002/hep.27819. Epub 2015 May 6.</citation>
    <PMID>25820757</PMID>
  </reference>
  <reference>
    <citation>Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature. 2012 Sep 13;489(7415):231-41. doi: 10.1038/nature11551. Review.</citation>
    <PMID>22972296</PMID>
  </reference>
  <reference>
    <citation>Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9.</citation>
    <PMID>444788</PMID>
  </reference>
  <reference>
    <citation>Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry. 2002 Mar;47(2):174-80.</citation>
    <PMID>11926080</PMID>
  </reference>
  <reference>
    <citation>Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57. Review.</citation>
    <PMID>9881538</PMID>
  </reference>
  <reference>
    <citation>Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978 Nov;133:429-35.</citation>
    <PMID>728692</PMID>
  </reference>
  <reference>
    <citation>Drago L, Toscano M, De Grandi R, Casini V, Pace F. Persisting changes of intestinal microbiota after bowel lavage and colonoscopy. Eur J Gastroenterol Hepatol. 2016 May;28(5):532-7. doi: 10.1097/MEG.0000000000000581.</citation>
    <PMID>27015015</PMID>
  </reference>
  <reference>
    <citation>Jalanka J, Salonen A, Salojärvi J, Ritari J, Immonen O, Marciani L, Gowland P, Hoad C, Garsed K, Lam C, Palva A, Spiller RC, de Vos WM. Effects of bowel cleansing on the intestinal microbiota. Gut. 2015 Oct;64(10):1562-8. doi: 10.1136/gutjnl-2014-307240. Epub 2014 Dec 19.</citation>
    <PMID>25527456</PMID>
  </reference>
  <reference>
    <citation>Rossen NG, MacDonald JK, de Vries EM, D'Haens GR, de Vos WM, Zoetendal EG, Ponsioen CY. Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. World J Gastroenterol. 2015 May 7;21(17):5359-71. doi: 10.3748/wjg.v21.i17.5359. Review.</citation>
    <PMID>25954111</PMID>
  </reference>
  <reference>
    <citation>Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes. 2013 Mar-Apr;4(2):125-35. doi: 10.4161/gmic.23571. Epub 2013 Jan 18.</citation>
    <PMID>23333862</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Women's College Hospital</investigator_affiliation>
    <investigator_full_name>Valerie Taylor</investigator_full_name>
    <investigator_title>Psychiatrist-in-Chief</investigator_title>
  </responsible_party>
  <keyword>Bipolar, Depression, FMT, Microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>both the descriptive and analyzed data, including individual patient data, will be submitted to the National Database for Clinical Trials related to Mental Illness (NDCT), which is part of the National Institute of Mental Health Data Archive (NDA). The data are de-identified and will be made available to qualified researchers, who have to request access to the dataset.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

